



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,595	09/23/2002	Sunil Ahuja	4003.001600	2489
20792	7590	08/24/2006	EXAMINER	
MYERS BIGEL SIBLEY & SAJOVEC PO BOX 37428 RALEIGH, NC 27627			SITTON, JEHANNE SOUAYA	
			ART UNIT	PAPER NUMBER
			1634	

DATE MAILED: 08/24/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Interview Summary	Application No.	Applicant(s)	
	10/089,595	AHUJA ET AL.	
	Examiner	Art Unit	
	Jehanne S. Sitton	1634	10 pages

All participants (applicant, applicant's representative, PTO personnel):

(1) Jehanne S. Sitton.

(3) _____.

(2) Mary Miller.

(4) _____.

Date of Interview: 15 August 2006.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____.

Claim(s) discussed: NA.

Identification of prior art discussed: Mummidj.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

encl. draft claim amendments

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Jehanne Sitton
Examiner's signature, if required

Summary of Record of Interview Requirements

Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant's attorney discussed draft claim amendments (attached). The examiner indicated that the claims would require clear indication of which positions were required to be genotyped to identify a particular haplotype because Mummidi taught genotyping positions in CCR5 and CCR2. The examiner indicated that she could not find a definition in the specification as to whether all 7 CCR5 SNPs, the 32 base pair deletion and the CCR2 I/V variant would be required to be genotyped to "detect the presence of" a specific haplotype pair, eg HHE/HHE. The examiner indicated that the specification included assessments of the haplotypes using less than all 9 variations, for example at page 4, a "signature motif" only indicated the 7 SNPs, while page 4 also discussed the different haplotypes with "obligate positions" which encompassed only a few of the 7 SNPs. Claims directed to testing for the presence or absence of specific haplotypes were also discussed. The examiner indicated that such claims encompass sequencing the entire specific region containing the 7 SNPs as well as the 32 base pair deletion and the CCR2 variation, which was taught by Mummidi. The examiner indicated that a response with claim amendments should include reference to the specification and the provisional application, by page and line number, for support.

Attorney Docket No. 9237.23
Applicant Serial No: 10/089,595
Page 4

DRAFT

IN THE CLAIMS

Please amend the claims as follows. This listing of claims replaces all prior versions.

1-55. (Canceled).

56. (Currently amended) ~~The method of claim 54, wherein said human subject is Caucasian and the presence of two HHE alleles is indicative of an increased risk of HIV-1 infection or disease progression~~A method of identifying a Caucasian human subject as having an increased risk of accelerated HIV-1 disease progression, comprising detecting the presence of a CCR5 haplotype pair HHE/HHE in the subject.

57. (Currently amended) ~~The method of claim 54, wherein said human subject is African-American and the presence of an HHC and an HHF*1 haplogroup, an HHC and an HHE haplogroup, two HHC haplogroups, or an HHC and an HHD haplogroup is indicative of an increased risk of HIV-1 infection or disease progression~~A method of identifying an African-American human subject as having an increased risk of accelerated HIV-1 disease progression, comprising detecting the presence of a CCR5 haplotype pair in the subject, wherein the haplotype pair is selected from the group consisting of:

- a) HHC/HHF*1;
- b) HHC/HHE;
- c) HHC/HHC; and
- d) HHC/HHD.

58. (Currently amended) ~~The method of claim 54, wherein said human subject is a child and the presence of an HHC and an HHE haplogroup, two HHE haplogroups, or an HHE haplogroup and an HHG*2 haplogroup is indicative of an increased risk of HIV-1 transmission, infection or disease progression~~A method of identifying a human child as having an increased risk of accelerated HIV-1 disease progression, comprising detecting the presence of a CCR5 haplotype pair in the child, wherein the haplotype pair is selected from the group consisting of:

- a) HHC/HHE;

Attorney Docket No. 9237.23
Applicant Serial No: 10/089,595
Page 5

DRAFT

b) HHE/HHE; and

c) HHE/HHG*2.

59-62. (Canceled).

63. (New) The method of claim 57, wherein the haplotype pair is HHC/HHF*1.

64. (New) The method of claim 57, wherein the haplotype pair is HHC/HHE.

65. (New) The method of claim 57, wherein the haplotype pair is HHC/HHC.

66. (New) The method of claim 57, wherein the haplotype pair is HHC/HHD.

67. (New) The method of claim 58, wherein the haplotype pair is HHC/HHE.

68. (New) The method of claim 58, wherein the haplotype pair is HHE/HHE.

69. (New) The method of claim 58, wherein the haplotype pair is HHE/HHG*2.

70. (New) A method of identifying a Caucasian human subject as having an increased risk of becoming infected with an HIV-1 virus, comprising detecting the presence of a CCR5 haplotype pair HHE/HHE in the subject.

71. (New) A method of identifying an African-American human subject as having an increased risk of becoming infected with an HIV-1 virus, comprising detecting the presence of a CCR5 haplotype pair in the subject, wherein the haplotype pair is selected from the group consisting of:

a) HHC/HHF*1;

b) HHC/HHE;

c) HHC/HHC; and

d) HHC/HHD.

Attorney Docket No. 9237.23
Applicant Serial No: 10/089,595
Page 6

DRAFT

72. (New) A method of identifying a human child as having an increased risk of becoming infected with an HIV-1 virus, comprising identifying a CCR5 haplotype pair in the child, wherein the haplotype pair is selected from the group consisting of:

- a) HHC/HHE;
- b) HHE/HHE; and
- c) HHE/HHG*2.

73. (New) The method of claim 71, wherein the haplotype pair is HHC/HHF*1.

74. (New) The method of claim 71, wherein the haplotype pair is HHC/HHE.

75. (New) The method of claim 71, wherein the haplotype pair is HHC/HHC.

76. (New) The method of claim 71, wherein the haplotype pair is HHC/HHD.

77. (New) The method of claim 72, wherein the haplotype pair is HHC/HHE.

78. (New) The method of claim 72, wherein the haplotype pair is HHE/HHE.

79. (New) The method of claim 72, wherein the haplotype is HHE/HHG*2.

80. (New) A method of testing a human subject for an increased risk of accelerated HIV-1 disease progression, comprising detecting the presence or absence of a CCR5 haplotype pair in the subject, wherein the haplotype pair is selected from the group consisting of:

- a) HHE/HHE;
- b) HHC/HHF*1;
- c) HHC/HHE;
- d) HHC/HHC;
- e) HHC/HHD; and
- f) HHE/HHG*2.

Attorney Docket No. 9237.23
Applicant Serial No: 10/089,595
Page 7

DRAFT

- 81. (New) The method of claim 80, wherein the haplotype pair is HHE/HHE.
- 82. (New) The method of claim 80, wherein the haplotype pair is HHC/HHF*1.
- 83. (New) The method of claim 80, wherein the haplotype pair is HHC/HHE.
- 84. (New) The method of claim 80, wherein the haplotype pair is HHC/HHD.
- 85. (New) The method of claim 80, wherein the haplotype pair is HHC/HHC.
- 86. (New) The method of claim 80, wherein the haplotype pair is HHE/HHG*2.

87. (New) A method of testing a human subject for an increased risk of becoming infected with an HIV-1 virus, comprising detecting the presence or absence of a CCR5 haplotype pair in the subject, wherein the haplotype pair is selected from the group consisting of:

- a) HHE/HHE;
- b) HHC/HHF*1;
- c) HHC/HHE;
- d) HHC/HHC;
- e) HHC/HHD; and
- f) HHE/HHG*2.

- 88. (New) The method of claim 87, wherein the haplotype pair is HHE/HHE;
- 89. (New) The method of claim 87, wherein the haplotype pair is HHC/HHF*1;
- 90. (New) The method of claim 87, wherein the haplotype pair is HHC/HHE;
- 91. (New) The method of claim 87, wherein the haplotype pair is HHC/HHC;
- 92. (New) The method of claim 87, wherein the haplotype pair is HHC/HHD.
- 93. (New) The method of claim 87, wherein the haplotype pair is HHE/HHG*2.

Attorney Docket No. 9237.23
Applicant Serial No: 10/089,595
Page 8

DRAFT

94. (New) A method of testing a Caucasian human subject for increased risk of accelerated HIV-1 disease progression, comprising detecting the presence or absence of a CCR5 haplotype pair HHE/HHE in the subject.

95. (New) A method of testing a Caucasian human subject for increased risk of becoming infected with an HIV-1 virus, comprising detecting the presence or absence of a CCR5 haplotype pair HHE/HHE in the subject.

96. (New) A method of testing an African-American human subject for increased risk of accelerated HIV-1 disease progression, comprising detecting the presence or absence of a CCR5 haplotype pair in the subject, wherein the haplotype pair is selected from the group consisting of:

- a) HHC/HHF*1;
- b) HHC/HHE;
- c) HHC/HHC; and
- d) HHC/HHD.

97. (New) The method of claim 96, wherein the haplotype pair is HHC/HHF*1.

98. (New) The method of claim 96, wherein the haplotype pair is HHC/HHE.

99. (New) The method of claim 96, wherein the haplotype pair is HHC/HHC.

100. (New) The method of claim 96, wherein the haplotype pair is HHC/HHD.

101. (New) A method of testing an African-American human subject for an increased risk of becoming infected with an HIV-1 virus, comprising detecting the presence or absence of a CCR5 haplotype pair in the subject, wherein the haplotype pair is selected from the group consisting of:

- a) HHC/HHF*1;
- b) HHC/HHE;

Attorney Docket No. 9237.23
Applicant Serial No: 10/089,595
Page 9

DRAFT

c) HHC/HHC; and

d) HHC/HHD.

102. (New) The method of claim 101, wherein the haplotype pair is HHC/HHF*1.

103. (New) The method of claim 101, wherein the haplotype pair is HHC/HHE.

104. (New) The method of claim 101, wherein the haplotype pair is HHC/HHC.

105. (New) The method of claim 101, wherein the haplotype pair is HHC/HHD.

106. (New) A method of testing a human child for an increased risk of accelerated HIV-1 disease progression, comprising detecting the presence or absence of a CCR5 haplotype pair in the child, wherein the haplotype pair is selected from the group consisting of:

a) HHC/HHE;

b) HHE/HHE; and

c) HHE/HHG*2.

107. (New) The method of claim 106, wherein the haplotype pair is HHC/HHE.

108. (New) The method of claim 106, wherein the haplotype pair is HHE/HHE.

109. (New) The method of claim 106, wherein the haplotype pair is HHE/HHG*2.

110. (New) A method of testing a human child for an increased risk of becoming infected with an HIV-1 virus, comprising detecting the presence or absence of a CCR5 haplotype pair in the child, wherein the haplotype pair is selected from the group consisting of:

a) HHC/HHE;

b) HHE/HHE; and

c) HHE/HHG*2.

Attorney Docket No. 9237.23
Applicant Serial No: 10/089,595
Page 10

DRAFT

111. (New) The method of claim 110, wherein the haplotype pair is HHC/HHE.
112. (New) The method of claim 110, wherein the haplotype pair is HHE/HHE.
113. (New) The method of claim 110, wherein the haplotype pair is HHE/HHG*2.
114. (New) A method of identifying a human subject as having an increased risk of accelerated HIV-1 disease progression, comprising testing for the presence or absence of a CCR5 haplotype pair in the subject, wherein the haplotype pair is selected from the group consisting of:
- a) HHE/HHE;
 - b) HHC/HHF*1;
 - c) HHC/HHE;
 - d) HHC/HHC;
 - e) HHC/HHD; and
 - f) HHE/HHG*2.
115. (New) A method of identifying a human subject as having an increased risk of becoming infected with an HIV-1 virus, comprising testing for the presence or absence of a CCR5 haplotype pair in the subject, wherein the haplotype pair is selected from the group consisting of:
- a) HHE/HHE;
 - b) HHC/HHF*1;
 - c) HHC/HHE;
 - d) HHC/HHC;
 - e) HHC/HHD; and
 - f) HHE/HHG*2.